Product Highlight - LANTUS

03 Sep 2021
                     It’s time to Upgrade1
Now available at an even more affordable price! 6

• Indicated to treat diabetes mellitus in adults, adolescents and children aged 2 years and above.7

• The 1st generation basal insulin analog in the market that offers 24-hour glycemic coverage.2

• Established insulin efficacy with improved safety vs. premixed insulins.3

• Lower rate of hypoglycemia vs. premixed insulin.3

• Convenient once-daily dosing for sustainable glycemic control.4

• Well-established long-term CV safety profile.5

Insulin Glargine 100 units/mL vial (Lantus®) – New SRP Php 1,376.50 per 10 mL vial (Savings of almost Php 1,380 from previous SRP)6

REFERENCES:
(1)
American Diabetes Association Diabetes Care 2021, Jan; 44(Supplement1): S111-S124. https://doi.org/10.2337/dc21-S009.
(2) Levien TL, Baker DE, White JR Jr, Campbell RK. Insulin glargine: a new basal insulin. Ann Pharmacother. 2002 Jun;36(6):1019-27. doi: 10.1345/aph.1A301. PMID: 12022906
(3) Kumar A, et al. PLoS One 2016;11(10):e0163350 [Study design: 52 week open label study of efficacy and safety of insulin degludec/insulin aspart (IDegAsp) once daily (OD) compared with insulin glargine U100 (IGlar) OD in insulin-naïve adults with T2DM]
(4) Gerstein HC, et al. N Engl J Med 2012;367:319–28
(5)
Gerstein HC, et al. Am Heart J 2008;155:26-32
(6) Based on Mercury Drug Retail price as of Jan 2021
(7) Lantus Prescribing Information

This material is strictly for HCPs only.

Related MIMS Drugs

Editor's Recommendations